Vivesto AB is a specialty pharmaceutical company dedicated to developing innovative treatment options for individuals facing challenging-to-treat cancers. With a focus on both human and veterinary oncology, Vivesto is at the forefront of creating a new generation of drugs. Their clinical-stage assets are specifically designed to target late-stage cancers, offering hope to patients in desperate need of effective therapies.

One of Vivesto's notable offerings is Apealea® (paclitaxel micellar), a groundbreaking treatment available to ovarian cancer patients in collaboration with Elevar Therapeutics, Inc. Additionally, Vivesto's development programs include Cantrixil, a clinical-stage drug addressing late-stage ovarian cancer, and docetaxel micellar, designed to combat advanced prostate cancer. What sets Vivesto apart is their proprietary drug delivery technology, which enhances solubility, efficacy, and safety of their treatments.

This groundbreaking approach ensures that patients receive the most effective and safe treatments possible. For individuals and investors who share Vivesto's mission, the opportunity to partner, join their team, or explore investment options is available. With a strong commitment to sustainability and corporate responsibility, Vivesto is revolutionizing cancer treatment and improving the lives of patients worldwide.

For more information, please visit their website or contact them directly